[Current status of intrathecal antifibrinolytic therapy with p-aminomethylbenzoic acid (PAMBA) in subarachnoid hemorrhages].
The blood-brain barrier is barely affected by slight or moderate subarachnoidal bleeding so that the p-aminomethylbenzoic acid (PAMBA) administered systemically for antifibrinolytic therapy does not attain the continuous level necessary in the cerebrospinal fluid. Thus the antifibrinolytic agent should be applied intrathecally because this would totally inhibit fibrinolytic activity in cerebrospinal fluid containing blood and during the wound healing of ruptured aneurysmas. The improvement in wound healing reduces the occurrence of rebleeding, especially during the first 10 days, and improves conditions for successful surgical intervention.
D010129:4-Aminobenzoic Acid / Q000627:therapeutic use*; D062365:Aminobenzoates / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007278:Injections, Spinal; D002532:Intracranial Aneurysm / Q000150:complications; D012008:Recurrence; D013345:Subarachnoid Hemorrhage / Q000097:blood / Q000188:drug therapy*; D062366:para-Aminobenzoates
D062365:Aminobenzoates; D000933:Antifibrinolytic Agents; D062366:para-Aminobenzoates; C015668:4-aminomethylbenzoic acid; D010129:4-Aminobenzoic Acid
Gegenwärtiger Stand der intrathekalen antifibrinolytischen Therapie mit p-Aminomethylbenzoesäure (PAMBA) bei Subarachnoidalblutungen.